Filtered By:
Condition: Stroke
Management: Centers for Disease Control and Prevention (CDC)

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 251 results found since Jan 2013.

Approaches in Prehospital Sepsis Screening
Discussion In the United States, sepsis is one of the leading causes of death, which requires timely identification and proper treatment (CDC, 2019; Guerra et al., 2020; Polito et al., 2015). Based upon a review of literature conducted from 2014 to 2018, the primary investigators could locate five prehospital EMS screening tools to assist EMS providers in identifying at-risk sepsis patients. The researchers explored how the modified SIRS and qSOFA scoring systems were used in hospital settings in addition to these five prehospital EMS screening tools. The Bas 90-30-90, Guerra, PRESEP, PRESS, and Robson tools have ove...
Source: JEMS Operations - January 5, 2021 Category: Emergency Medicine Authors: JEMS Staff Tags: Exclusives Patient Care EMS EMT Paramedic Prehospital Sepsis Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Nomogram Including Neutrophil-to-Lymphocyte Ratio for the Prediction of Stroke-Associated Infections
Stroke has been a leading cause of mortality in China. Stroke-associated infections (SAI) are common complications, occurring in 5–65% of stroke patients. Faced with SAI, clinicians often are placed in a considerable dilemma. On the one hand, preventive overuse of antibiotics will lead to the emergence of drug-resistant bacteria. On the other hand, treatment delay of the infection will likely result in a poor outcome. Therefore, it is necessary to determine the early predictors of post-stroke infection to screen patients with high infection risk for early clinical intervention, thereby promoting and improving survival ra...
Source: Frontiers in Neurology - November 2, 2020 Category: Neurology Source Type: research

UCLA researchers study genetics ’ role in COVID-19 susceptibility, severity
“One of the most troubling things about COVID-19 is that we have a limited ability to predict how sick a specific individual will get,” said Dr. Daniel Geschwind.Geschwind is the MacDonald Distinguished Professor in Human Genetics at theDavid Geffen School of Medicine at UCLA and a member of theEli and Edythe Broad Center of  Regenerative Medicine and Stem Cell Research at UCLA. And he ’s part of a team of UCLA scientists conducting research to learn why certain people get sick from the virus that causes COVID-19 — and why others don’t.Millions of people around the world have been infected with SARS-CoV-2, the v...
Source: UCLA Newsroom: Health Sciences - October 26, 2020 Category: Universities & Medical Training Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

CDC: Meeting of the Community Preventive Services Task Force (CPSTF)
The Centers for Disease Control and Prevention will hold a virtual public meeting of the Community Preventive Services Task Force (CPSTF) on October 21-22, 2020. The CPSTF is charged with identifying community preventive programs, services, and policies that increase healthy longevity and improve quality of life, while saving money. The agenda will consist of deliberation on systematic reviews of literature on topics including heart disease and stroke, obesity, and asthma.
Source: Federal Register updates via the Rural Assistance Center - September 15, 2020 Category: Rural Health Source Type: news

CERENOVUS Launches New Suite of Technologies to Advance Stroke Treatment
IRVINE, CA – September 9, 2020 – CERENOVUS, part of Johnson & Johnson Medical Devices Companies* today announced that it has launched CERENOVUS Stroke Solutions™, which includes a suite of three devices designed to aid physicians in clot removal procedures. The announcement was made during the virtual European Society of Minimally Invasive Neurological Therapy (ESMINT).Strokes are the second leading cause of death globally, and account for an estimated 140,000 deaths in the United States each year.[i],[ii] Over half of stroke survivors become chronically disabled placing an estimated $34 billion economic burden o...
Source: Johnson and Johnson - September 9, 2020 Category: Pharmaceuticals Source Type: news

Years of life lost from ischaemic and haemorrhagic stroke related to ambient nitrogen dioxide exposure: A multicity study in China.
Abstract Few multicity studies have been conducted in developing countries to distinguish the acute effects of ambient nitrogen dioxide (NO2) on the years of life lost (YLL) from different subtypes of stroke. We aimed to differentiate the associations between NO2 exposure and YLL from major pathological types of stroke in China, and estimate the relevant economic loss. A time-series study was conducted to explore the associations between short-term NO2 exposure and YLL from ischaemic and haemorrhagic stroke from 2013 to 2017 in 48 Chinese cities. Daily NO2 data and stroke mortality counts for each city were obtain...
Source: Ecotoxicology and Environmental Safety - September 7, 2020 Category: Environmental Health Authors: Li J, Huang J, Wang Y, Yin P, Wang L, Liu Y, Pan X, Zhou M, Li G Tags: Ecotoxicol Environ Saf Source Type: research

Cinnamon May Slow Progression To Type 2 Diabetes, Boston Study Finds
(CNN) — Cinnamon may improve blood sugar control in people with a condition known as prediabetes and may slow the progression to type 2 diabetes, according to a new pilot study of 51 people with elevated blood sugars. “We are looking for safe, durable and cost-effective approaches to reduce the progression from prediabetes to type 2 diabetes,” said study author Dr. Giulio Romeo, a staff physician at Boston’s Joslin Diabetes Center and the division of endocrinology at Beth Israel Deaconess Medical Center. The study published Tuesday in the Journal of the Endocrine Society. “Our 12-week study sh...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 21, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Cinnamon CNN Diabetes Source Type: news

CDC Head Estimates U.S. Coronavirus Cases Might be 10 Times Higher Than Data Show
In a press briefing on June 25, Dr. Robert Redfield, director of the U.S. Centers for Disease Control and Prevention (CDC), said that the current official count of COVID-19 cases in the U.S. may actually be a drastic underestimate. Redfield said the new, much-higher estimate, is based on growing data from antibody testing, which picks up the presence of immune cells that react to SARS-CoV-2, the virus that causes COVID-19. People will test positive for antibodies to the virus if they have been infected—whether or not they ever got sick or even developed symptoms. Previously, testing was focused only on those with sym...
Source: TIME: Health - June 25, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news